Paclitaxel Injection USP 100 mg /30 mg is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin. Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
3s corporation is Supplier,Exporter ,Wholesaler for Paclitaxel Injection USP 100 mg /30 mg in India.
India has many manufacturers who manufacture Paclitaxel Injection USP 100 mg /30 mg .To know more contact us.
Bone marrow suppression (primarily neutropenia) is dose-dependent and is the dose-limiting toxicity. Neutrophil nadirs occurred at a median of 11 days. Paclitaxel Injection should not be administered to patients with baseline neutrophil counts of less than 1500 cells/mm3 ( < 1000 cells/mm3 for patients with KS). Frequent monitoring of blood counts should be instituted during Paclitaxel Injection treatment.
Call doctor at once if patient has a serious side effect such as:
fever, chills, body aches, flu symptoms, sores in mouth and throat;
pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;